The Food and Drug Administration is already considering child-sized administration of the Pfizer vaccine for elementary school children.
Moderna said on Monday that low-dose COVID-19 vaccines seem to work at ages 6-11 as manufacturers are working towards expanding injections into children.
Pfizer’s child-sized vaccine doses from competitors are widely used and have been evaluated by the Food and Drug Administration for approximately the same age group (from 5 years). The vaccine has already been approved for everyone over the age of 12.
Moderna has not yet agreed to provide vaccines to teens, but while waiting, they are studying low doses for young children. The researchers tested two shots of children aged 6 to 11 years, each containing half the dose given to adults, at monthly intervals.
Preliminary results showed that vaccinated children developed antibodies that fight viruses similar to the levels produced by young adults after full injection, Moderna said in a press release.
The study included 4,753 children aged 6 to 11 years who received either the vaccine or dummy shots. Moderna said that vaccinated young people, like adults, have temporary side effects such as fatigue, headaches, fever, and pain at the injection site.
This study was too small to find very rare side effects, such as occasional heart inflammation, mainly among young men, after either the Moderna or Pfizer vaccines.
Moderna said it will soon submit pediatric data to the FDA and global regulators. The FDA has not yet decided on its application to extend vaccination from 12 to 17 years old, but in some countries it has cleared Moderna’s adolescent vaccination.
However, if the FDA permits small doses of Pfizer and BioNTech vaccines between the ages of 5 and 11, the United States will begin vaccination of children under the age of 12 sometime next month. Pfizer last week proved that child-sized doses were nearly 91% effective in preventing symptomatic COVID-19 in younger age groups, despite the widespread prevalence of highly contagious delta variants. I reported.
FDA advisors will discuss Pfizer’s evidence at a public meeting on Tuesday. If the agency approves Pfizer’s child shots, the Centers for Disease Control and Prevention the following week is set up to recommend who should receive them.
The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.
Moderna: Low-dose COVID-19 shots are effective for children 6-11 years
Source link Moderna: Low-dose COVID-19 shots are effective for children 6-11 years